Article · Wikipedia archive · Last revised Jul 27, 2026

2CB-5OCD3

2CB-5OCD3, also known as 5-trideuteromethoxy-2C-B, is a serotonin 5-HT2A receptor agonist and possible psychedelic drug of the phenethylamine and 2C families. It is the isotopologue of 2C-B in which the three hydrogen atoms of the methoxy group at the 5 position have been replaced with the deuterium isotopes. The drug shows similar serotonin 5-HT2A receptor pharmacodynamics and metabolism as 2C-B in vitro. The chemical synthesis of 2CB-5OCD3 has been described. 2CB-5OCD3 was developed by Nicholas V. Cozzi and Paul F. Daley of the Alexander Shulgin Research Institute (ASRI). It was patented in 2024 and was first described in the scientific literature in 2026.

Last revised
Jul 27, 2026
Read time
≈ 1 min
Length
191 w
Citations
12
Source
Wikipedia ↗
2CB-5OCD3
Clinical data
Other names2C-B-5-OCD3; 5-Trideuteromethoxy-2C-B; 4-Bromo-2-methoxy-5-trideuteromethoxyphenethylamine; 2-(4-Bromo-2-methoxy-5-(methoxy-d3)phenyl)ethan-1-amine
Drug classSerotonin 5-HT2A receptor agonist; Possible serotonergic psychedelic or hallucinogen
ATC code
  • None
Identifiers
  • 2-[4-bromo-2-methoxy-5-(trideuteriomethoxy)phenyl]ethanamine
PubChem CID
Chemical and physical data
FormulaC10H14BrNO2
Molar mass260.131 g·mol−1
3D model (JSmol)
  • [2H]C([2H])([2H])OC1=C(C=C(C(=C1)CCN)OC)Br
  • InChI=1S/C10H14BrNO2/c1-13-9-6-8(11)10(14-2)5-7(9)3-4-12/h5-6H,3-4,12H2,1-2H3/i2D3
  • Key:YMHOBZXQZVXHBM-BMSJAHLVSA-N

2CB-5OCD3, also known as 5-trideuteromethoxy-2C-B, is a serotonin 5-HT2A receptor agonist and possible psychedelic drug of the phenethylamine and 2C families.12 It is the isotopologue of 2C-B in which the three hydrogen atoms of the methoxy group at the 5 position have been replaced with the deuterium isotopes.12 The drug shows similar serotonin 5-HT2A receptor pharmacodynamics and metabolism as 2C-B in vitro.12 The chemical synthesis of 2CB-5OCD3 has been described.12 2CB-5OCD3 was developed by Nicholas V. Cozzi and Paul F. Daley of the Alexander Shulgin Research Institute (ASRI).12 It was patented in 20242 and was first described in the scientific literature in 2026.1

See also

See also

References

References

  1. Cozzi NV (June 2026). "Serotonin 2A receptor binding, functional activity, and in vitro metabolism of two trideuteromethoxy 2C-B isotopologues". Naunyn-Schmiedeberg's Archives of Pharmacology. doi:10.1007/s00210-026-05566-5. PMID 42313138.
  2. US 20240408038, Daley PF, Cozzi NV, "Substituted phenylalkylamines", published 2024-12-12, issued 2025-11-11, assigned to Alexander Shulgin Research Institute Inc